Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with type 2 diabetes mellitus (T2DM)~* Have HbA1c between ≥7.5% and ≤11%~* Have been treated for at least 90 days prior to day of screening with once or twice daily basal insulin with or without stable dose of metformin ≥1500 mg/day and up to maximum approved dose per country specific approved label, sulfonylureas or dipeptidyl peptidase 4 inhibitors~* Be of stable weight (± 5%) for at least 90 days~* Have a BMI ≥23 kilograms per meter squared (kg/m²) and ≤45 kg/m² at screening~Exclusion Criteria~* Have type 1 diabetes mellitus~* Have had chronic or acute pancreatitis any time prior to study entry~* Have proliferative diabetic retinopathy or diabetic macular edema or nonproliferative diabetic retinopathy requiring immediate or urgent treatment~* Have disorders associated with slowed emptying of the stomach, have had any stomach surgeries for the purpose of weight loss, or are chronically taking drugs that directly affect gastrointestinal motility~* Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months~* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2~* Have been taking weight loss drugs, including over-the-counter medications during the last 3 months~* Have an estimated glomerular filtration rate \<30 mL/minute/1.73 m² \[for participants on metformin, estimated glomerular filtration rate \<45 mL/min/1.73 m2 (or lower than the country-specific threshold for using the protocol-required dose of metformin per local label)\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
- 10 mg Tirzepatide (Type: EXPERIMENTAL): 10 mg tirzepatide administered SC once a week.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): 15 mg tirzepatide administered SC once a week.
- Insulin Lispro (Type: ACTIVE_COMPARATOR): Insulin lispro 100 units per milliliter (U100) administered SC three times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).